Találati lista | Tudóstér

001-es BibID:	BIBFORM118901
035-os BibID:	(WoS)001181243400001 (Scopus)85187190105
Első szerző:	Csiki Emese (onkoradiológus)
Cím:	Stereotactic body radiotherapy in lung cancer : a contemporary review / Csiki Emese, Simon Mihály, Papp Judit, Barabás Márton, Mikáczó Johanna, Gál Kristóf, Sipos Dávid, Kovács Árpád
Dátum:	2024
ISSN:	1219-4956 1532-2807
Megjegyzések:	The treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine the size, localization and extent of the lung tumor. The introduction of novel and further developed planning (contouring guidelines, diagnostic image application, planning systems) and delivery techniques (motion management, image guided radiotherapy) led to lower rates of side effects and more conformal target volume coverage. The purpose of this study is to summarize the current developments, randomised studies, guidelines about lung SBRT, with emphasis on the possibility of increasing local control and overall rates in "fit," operable patients as well, so SBRT would be eligible in place of surgery.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Pathology & Oncology Research. - 161 (2024), p. 1-13. -
További szerzők:	Simon Mihály Papp Judit (1971-) (onkoradiológus) Barabás Márton (1994-) (orvos) Mikáczó Johanna (1997-) (általános orvos) Gál Kristóf (1994-) (orvos) Sipos Dávid Kovács Árpád (1979-) (onkoradiológus, klinikai onkológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM121026
035-os BibID:	(Scopus)85192759884
Első szerző:	Debreczeni-Máté Zsanett
Cím:	Recurrence Patterns after Radiotherapy for Glioblastoma with [(11)C]methionine Positron Emission Tomography-Guided Irradiation for Target Volume Optimization / Zsanett Debreczeni-Máté, Imre Törő, Mihaly Simon, Kristof Gál, Marton Barabás, David Sipos, Arpad Kovács
Dátum:	2024
ISSN:	2075-4418
Megjegyzések:	Abstract: 11C methionine (11C-MET) is increasingly being used in addition to contrast-enhanced MRI to plan for radiotherapy of patients with glioblastomas. This study aimed to assess the recurrence pattern quantitatively. Glioblastoma patients undergoing 11C-MET PET examination before primary radiotherapy from 2018 to 2023 were included in the analysis. A clinical target volume was manually created and fused with MRI-based gross tumor volumes and MET PET-based biological target volume. The recurrence was noted as an area of contrast enhancement on the first MRI scan, which showed progression. The recurrent tumor was identified on the radiological MR images in terms of recurrent tumor volume, and recurrences were classified as central, in-field, marginal, or ex-field tumors. We then compared the MET-PET-defined biological target volume with the MRI-defined recurrent tumor volume regarding spatial overlap (the Dice coefficient) and the Hausdorff distance. Most recurrences occurred locally within the primary tumor area (64.8%). The mean Hausdorff distance was 39.4 mm (SD 32.25), and the mean Dice coefficient was 0.30 (SD 0.22). In patients with glioblastoma, the analysis of the recurrence pattern has been mainly based on FET-PET. Our study confirms that the recurrence pattern after gross tumor volume-based treatment contoured by MET-PET is consistent with the FET-PET-based treatment described in the literature.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk 11C MET PET glioblastoma recurrence pattern
Megjelenés:	Diagnostics. - 14 : 9 (2024), p. 1-12. -
További szerzők:	Törő Imre Simon Mihály Gál Kristóf (1994-) (orvos) Barabás Márton (1994-) (orvos) Sipos Dávid Kovács Árpád (1979-) (onkoradiológus, klinikai onkológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM131798
Első szerző:	Freihat, Omar
Cím:	Three-dimensional conformal therapy vs. intensity modulated radiation therapy in GBM : survival, dosimetry, and side effects a systematic review and meta-analysis / Freihat Omar, Sipos David, Kotb Reham, Aamir Maria, Solymosi Dóra, Gál Kristóf, Mihály Simon, Kovacs Arpad
Dátum:	2025
ISSN:	2296-424X
Megjegyzések:	Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor with a poor prognosis, often managed with radiotherapy. Two primary modalities, three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT), differ in their precision and impact on survival, side effects, and OAR sparing. However, their comparative benefits remain unclear. This meta-analysis evaluates 3D-CRT and IMRT in GBM treatment, focusing on dosimetric parameters, toxicity, and OAR sparing, with an exploratory analysis of overall survival (OS). Methods: A systematic review of 19 studies was conducted, comparing dosimetric and side effects, including planning target volume (PTV) doses (Dmean, Dmax, and Dmin), conformity and homogeneity indices, and OAR sparing. Results: IMRT provided significant dosimetric advantages, with higher PTV Dmean (mean difference (MD) 1.26 Gy; 95% CI: 0.22?2.31; P = 0.02) and better conformity index (MD ?0.21; 95% CI: ?0.33 to ?0.08; P = 0.001). IMRT significantly reduced doses to healthy brain (MD ?1.08 Gy; 95% CI: ?2.08 to ?0.09; P = 0.03), brainstem (MD ?0.66 Gy; 95% CI: ?1.18 to ?0.15; P = 0.01), optic chiasm (MD ?4.93 Gy; 95% CI: ?9.15 to ?0.70; P = 0.02), right optic nerve (MD -5.82 Gy; 95% CI: ?9.49 to ?2.15; P = 0.002), and left optic nerve (MD ?1.20 Gy; 95% CI: ?1.77 to ?0.63; P < 0.0001). Conclusion: IMRT provides significant dosimetric benefits and potentially lower toxicity compared to 3D-CRT in GBM treatment. While an exploratory analysis suggests a possible OS benefit, this requires cautious interpretation due to study limitations. IMRT's precision supports its use in GBM treatment.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk glioblastoma multiforme (GBM) intensity-modulated radiotherapy (IMRT) threedimensional conformal radiotherapy (3D-CRT) overall survival (OS) organs at risk glioblastoma multiforme (GBM) dosimetry toxicity organs at risk
Megjelenés:	Frontiers in Physics. - 13 (2025), p. 1-14. -
További szerzők:	Sipos Dávid Kotb, Reham Aamir, Maria Solymosi Dóra Gál Kristóf (1994-) (orvos) Mihály Simon Kovács Árpád (1979-) (onkoradiológus, klinikai onkológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM118614
035-os BibID:	(WoS)001171752500001 (Scopus)85186741412
Első szerző:	Kovács Árpád (onkoradiológus, klinikai onkológus)
Cím:	LINAC-based SBRT in treating early-stage NSCLC patients : single institution experience and survival data analysis / Kovács Árpád, Trási Krisztina, Barabás Márton, Gál Kristóf, Csiki Emese, Sipos Dávid, Papp Judit, Simon Mihály
Dátum:	2024
ISSN:	1219-4956 1532-2807
Megjegyzések:	Aim: This single institute prospective study aimed to evaluate the feasibility of LINAC-based stereotactic body radiotherapy (SBRT) in treating patients with early-stage non-small cell lung cancer (NSLSC). We focused on the survival data with the local and distant control profiles and the cancer- and non-cancer-specific survival. Treatment-related side effects were also collected and analyzed.Methods: Patients with early-stage NSCLC between January 2018 and October 2021 were included in our prospective study; a total of 77 patients receiving LINAC-based SBRT were analyzed. All patients had pretreatment multidisciplinary tumor board decisions on SBRT. The average patient age was 68.8 years (median: 70 years, range: 52-82); 70 patients were in ECOG 0 status (91%), while seven patients were in ECOG 1-2 status (9%). 52% of the patients (40) had histologically verified NSCLC, and the other 48% were verified based on PETCT results. We applied the SBRT scheme 8 x 7.5 Gy for central tumors (74%) or 4 x 12 Gy for peripheral tumors (26%).Results: The mean follow-up time was 25.4 months (median 23, range 18-50). The Kaplan-Meier estimation for overall survival in patients receiving LINAC-based SBRT was 41.67 months. Of the 77 patients treated by SBRT, death was reported for 17 patients (9 cases cancer-specific, 8 cases non-cancer specific reason). The mean local tumor control was 34.25 months (range 8.4-41), and the mean systemic control was 24.24 months (range 7-25). During the treatments, no Grade I-II were reported; in 30 cases, Grade I non-symptomatic treatment-related lung fibrosis and two asymptomatic rib fractures were reported.Conclusion: In the treatment of early-stage NSCLC, LINAC-based SBRT can be a feasible alternative to surgery. Although we reported worse OS data in our patient cohort compared to the literature, the higher older average age and the initial worse general condition (ECOG1-2) in our patient cohort appear to be the reason for this difference. With the comparable local control and survival data and the favorable side effect profile, SBRT might be preferable over surgery in selected cases.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk VATS NSCLC SBRT LINAC-based SBRT early stage
Megjelenés:	Pathology & Oncology Research. - 30 (2024), p. 1-6. -
További szerzők:	Loós-Trási Krisztina (1996-) (orvos) Barabás Márton (1994-) (orvos) Gál Kristóf (1994-) (orvos) Csiki Emese (1986-) (onkoradiológus) Sipos Dávid Papp Judit (1971-) (onkoradiológus) Simon Mihály (1981-) (Fizikus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: